Botulinum toxin injections into the detrusor

BJU International

Volumn 108, Issue 9, 2011, Pages 1528-1537

  Wöllner, Jens ^a,b   Kessler, Thomas M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ACETYLCHOLINE RELEASE; ARTICLE; DETRUSOR MUSCLE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE; MINIMALLY INVASIVE PROCEDURE; NEEDLE; OVERACTIVE BLADDER; PARASYMPATHETIC INNERVATION; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SURGICAL PROCEDURES, MINIMALLY INVASIVE; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 80055006016     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10675.x     Document Type: Article

References (10)

1. Abrams P, Cardozo L, Fall M, et al,. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78 (Pubitemid 34195211)
2. Klotz T, Bruggenjurgen B, Burkart M, Resch A,. The economic costs of overactive bladder in Germany. Eur Urol 2007; 51: 1654-63 (Pubitemid 46634742)
3. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D,. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-7 (Pubitemid 30637604)
4. Schurch B, Schmid DM, Stohrer M,. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665 (Pubitemid 30118430)
5. Apostolidis A, Dasgupta P, Denys P, et al,. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55: 100-19
6. Mangera A, Andersson KE, Apostolidis A, et al,. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). Eur Urol 2011, 60: 784-95
7. Apostolidis A, Dasgupta P, Fowler CJ,. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-50 (Pubitemid 43374724)
8. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P,. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92: 325-6 (Pubitemid 36966603)
9. Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ,. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009; 113: 1046-51
10. Ghulam AT, Kessler M, Bachmann LM, Haller U, Kessler TM,. Patients' satisfaction with the preoperative informed consent procedure: a multicenter questionnaire survey in Switzerland. Mayo Clin Proc 2006; 81: 307-12 (Pubitemid 43334624)